|
JP4309135B2
(ja)
|
2001-05-05 |
2009-08-05 |
スミスクライン ビーチャム ピー エル シー |
Ｎ−アロイルサイクリックアミン
|
|
GB0115862D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB0124463D0
(en)
*
|
2001-10-11 |
2001-12-05 |
Smithkline Beecham Plc |
Compounds
|
|
GB0127145D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
|
GB0130335D0
(en)
*
|
2001-12-19 |
2002-02-06 |
Smithkline Beecham Plc |
Compounds
|
|
RU2005103398A
(ru)
|
2002-07-09 |
2006-06-27 |
Актелион Фармасьютикалз Лтд. (Ch) |
Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
|
|
WO2004026866A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Glaxo Group Limited |
N-aroyl cyclic amines as orexin receptor antagonists
|
|
AU2003294671A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Actelion Pharmaceuticals Ltd. |
Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
|
|
GB0225938D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0225944D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
CA2520839A1
(en)
|
2003-04-28 |
2004-11-11 |
Actelion Pharmaceuticals Ltd |
Quinoxalinone-3- one derivatives as orexin receptor antagonists
|
|
HRP20150371T1
(hr)
|
2004-03-01 |
2015-05-08 |
Actelion Pharmaceuticals Ltd. |
Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
|
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
|
US20060178307A1
(en)
*
|
2005-01-26 |
2006-08-10 |
The Regents Of The University Of California |
Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
|
|
US7501395B2
(en)
|
2005-04-25 |
2009-03-10 |
Eisai R & D Management Co., Ltd. |
Method of screening for antianxiety drugs
|
|
WO2006126074A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Orchid Research Laboratories Limited |
Heterocyclic derivatives
|
|
WO2007136790A2
(en)
*
|
2006-05-18 |
2007-11-29 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
US8618102B2
(en)
|
2006-07-14 |
2013-12-31 |
Merck Sharp & Dohme Corp. |
Bridged diazepan orexin receptor antagonists
|
|
EP2079690B1
(en)
*
|
2006-09-29 |
2010-09-15 |
Actelion Pharmaceuticals Ltd. |
3-aza-bicyclo[3.1.0]hexane derivatives
|
|
PE20081229A1
(es)
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
WO2008065626A2
(en)
|
2006-12-01 |
2008-06-05 |
Actelion Pharmaceuticals Ltd |
3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
|
|
CL2007003827A1
(es)
|
2006-12-28 |
2008-09-26 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
|
|
CL2008000836A1
(es)
*
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
AU2008255005B2
(en)
|
2007-05-18 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
OXO bridged diazepan orexin receptor antagonists
|
|
US8030495B2
(en)
|
2007-05-23 |
2011-10-04 |
Coleman Paul J |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
HRP20120240T1
(hr)
|
2007-05-23 |
2012-04-30 |
Merck Sharp & Dohme Corp. |
Piridil piperidin antagonisti receptora za oreksin
|
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
CA2691373A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Actelion Pharmaceuticals Ltd |
3-aza-bicyclo[3.3.0]octane compounds
|
|
NZ583487A
(en)
*
|
2007-07-27 |
2011-09-30 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.3.0]octane derivatives
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
EP2207778A2
(en)
|
2007-09-24 |
2010-07-21 |
Actelion Pharmaceuticals Ltd. |
Pyrrolidines and piperidines as orexin receptor antagonists
|
|
NZ588080A
(en)
|
2008-02-21 |
2012-04-27 |
Actelion Pharmaceuticals Ltd |
2-Aza-bicyclo[2.2.1]heptane derivatives
|
|
CA2722347A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Actelion Pharmaceuticals Ltd |
Piperidine and pyrrolidine compounds
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2729985A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Actelion Pharmaceuticals Ltd |
Thiazolidine compounds as orexin receptor antagonists
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
EP2362731B1
(en)
|
2008-10-31 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
BRPI0922353A2
(pt)
|
2008-12-02 |
2018-06-05 |
Glaxo Group Ltd |
Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
EP2421850A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
|
|
EP2470523A1
(en)
|
2009-08-24 |
2012-07-04 |
Glaxo Group Limited |
5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
|
|
JP2013502448A
(ja)
|
2009-08-24 |
2013-01-24 |
グラクソ グループ リミテッド |
オレキシンアンタゴニストとして用いられるピペリジン誘導体
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
EP2811997B1
(en)
|
2012-02-07 |
2018-04-11 |
Eolas Therapeutics Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
LT2855453T
(lt)
|
2012-06-04 |
2017-02-27 |
Actelion Pharmaceuticals Ltd. |
Benzimidazolo prolino dariniai
|
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US9493446B2
(en)
|
2012-10-10 |
2016-11-15 |
Actelion Pharmaceuticals Ltd. |
Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
|
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
抗糖尿病二環式化合物
|
|
EP2970241A1
(en)
|
2013-03-12 |
2016-01-20 |
Actelion Pharmaceuticals Ltd. |
Azetidine amide derivatives as orexin receptor antagonists
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
PT3077389T
(pt)
|
2013-12-03 |
2017-12-15 |
Idorsia Pharmaceuticals Ltd |
Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
|
|
SI3077391T1
(sl)
|
2013-12-04 |
2018-11-30 |
Idorsia Pharmaceuticals Ltd |
Uporaba benzimidazol-prolinskih derivatov
|
|
WO2016025669A1
(en)
|
2014-08-13 |
2016-02-18 |
Eolas Therapeutics, Inc. |
Difluoropyrrolidines as orexin receptor modulators
|
|
PL3414241T3
(pl)
|
2016-02-12 |
2022-10-03 |
Astrazeneca Ab |
Piperydyny podstawione halo jako modulatory receptora oreksyny
|
|
EP3454857A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
KR20220016918A
(ko)
|
2019-06-04 |
2022-02-10 |
하거 바이오사이언시즈, 엘엘씨 |
오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법
|
|
TW202400149A
(zh)
|
2022-05-13 |
2024-01-01 |
瑞士商愛杜西亞製藥有限公司 |
經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
|
|
GB202311281D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|
|
GB202311280D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|